Compare ERII & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | OVID |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 522.6M |
| IPO Year | 2008 | 2017 |
| Metric | ERII | OVID |
|---|---|---|
| Price | $8.07 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $17.07 | $4.60 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,987,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.55 | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $7.94 | $0.27 |
| 52 Week High | $18.31 | $3.11 |
| Indicator | ERII | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 42.80 |
| Support Level | N/A | $2.33 |
| Resistance Level | $11.58 | $2.74 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 9.06 | 19.77 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.